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Essentials:  
 An international collaboration provide a consensus for clinical 
definitions 
 We standardize terminology in TMAs and thrombotic 
thrombocytopenic purpura. 
 We define TTP, differential diagnosis, monitoring disease and  
response to treatment. 
 We describe requirements for ADAMTS13 assays for diagnosis 
and follow up of TTP patients.  
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Abstract: 
Background Thrombotic thrombocytopenic purpura (TTP) and hemolytic 
uremic syndrome (HUS) are two important acute conditions to diagnose. 
Thrombotic Microangiopathy is a broad pathophysiological process that leads 
to microangiopathic hemolytic anemia , thrombocytopenia and involves 
capillary and small vessel platelet aggregates. The most common cause 
being disseminated intravascular coagulation (DIC), which may be 
differentiated by abnormal coagulation. Clinically, a number of conditions 
present with  microangiopathic hemolytic anemia and thrombocytopenia 
(MAHAT),  including cancer, infection, transplantation, drugs, autoimmune 
disease and pre eclampsia (PE) and HELLP (Hemolysis, Elevated Liver 
enzymes, Low Platelet count) syndrome in pregnancy. Despite overlapping 
clinical presentations, TTP and HUS have distinct pathophysiology and 
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treatment pathways.  Objectives: Presented is a consensus document from 
an international working group on TTP and associated TMAs (thrombotic 
microangiopathies). Methods: The international working group has proposed 
definitions and terminology based on published information and consensus 
based recommendations.  Conclusion: The consensus aims to aid clinical 
decisions but also future studies and trials, utilizing standardized definitions. It 
presents classification of the causes of TMA, and criteria for clinical response, 
remission and relapse of congenital and immune mediated TTP. 
Introduction 
The elucidation of the pathophysiology of TTP and HUS, in the past 20 years, 
has transformed our understanding of the phenotypes, genotypes and 
therapies for these life-threatening conditions. Work on standardization has 
been addressed [1], but this document aims to develop robust criteria for 
future clinical use, studies and trials. Clinical and pathophysiologic features of 
TTP, atypical Hemolytic Uremic Syndrome (aHUS) and disorders with similar 
presentations, their investigation and subsequent management vary. This 
consensus document aims to rationalize and standardize definitions.  
Conditions often included in the initial differential diagnosis of TTP are 
discussed. Definitions for remission, refractory and relapsing disease are 
defined. ADAMTS 13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) assays are central to diagnosis 
and are discussed. We therefore also describe the minimum requirements for 
validation of current and future assays. 
Methods:  
 
The development of this document involved key international, primarily 
clinical, experts in TTP and related TMAs. The concept was supported by the 
European Hematology Association, scientific working group (EHA-SWG), 
platelet group, who have endorsed this collaboration. Members of the group 
have met at key international meetings, including EHA, International Society 
of Thrombosis and Hemostasis (ISTH) and American Society of Hematology 
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(ASH) and all versions of the document have been reviewed and edited by the 
authors. Articles were identified by a computer-assisted search of the 
literature published in English using the National Library of Medicine PubMed 
database. The authors also undertook a focused review of the available 
literature. Where there was a lack of robust evidence, the international 
working group concluded a consensus-based approach was preferable. The 
conclusions are relevant to both children and adults. 
 
Thrombotic Microangiopathy  
The term TMA is a pathological term used to describe occlusive microvascular 
or macrovascular disease, often with intraluminal thrombus formation, but is 
also defined clinically by microangiopathic hemolytic anemia and 
thrombocytopenia (MAHAT). This does not specifically define a condition; 
therefore further investigations are required to identify the underlying cause 
for the presentation of a TMA, including TTP (Figure 1).  
Pathological Features of TMAs 
A number of different pathological entities have been identified, including: 
(i) von Willebrand factor (VWF)-platelet thrombosis; seen with severe 
ADAMTS13 deficiency related to anti-ADAMTS13 antibodies or a congenital 
absence of ADAMTS13, the hallmark of TTP. The characteristic pathology of 
TTP is the presence of ultra large VWF multimers and VWF and platelet rich 
thrombi in arterioles and capillaries[2, 3]. Presentation with large vessel 
thrombosis (stroke or myocardial infarction) is believed to result from vascular 
injury caused by thrombosis of the vasa vasorum   
  
(ii) Fibrin-platelet thrombosis; commonly seen in disseminated intravascular 
coagulation (DIC) [4] but occasionally seen in catastrophic antiphospholipid 
syndrome (CAPS), heparin induced thrombocytopenia (HIT), and 
HELLP syndrome. 
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 (iii)  Thrombotic Microangiopathy; characterized by endothelial swelling or 
disruption associated with hyalinosis or fibrinoid necrosis, usually without an 
inflammatory cell infiltrate. Chronic TMA is associated with myointimal 
proliferation resulting in concentric rings of cells and matrix surrounding small 
vessels (sometimes termed onion skinning), which can be indistinguishable 
from the effects of chronic hypertension. Intraluminal thrombosis is frequently 
present, but is not required for the diagnosis [5]. Examples include MAHAT 
caused by shiga toxin, complement dysregulation and drugs (eg gemcitabine). 
 
(iv) Vasculopathy/vasculitis; changes involve not only endothelial cells and 
intima, may be autoimmune (e.g. lupus vasculitis [6], scleroderma renal crisis 
[7]) or infectious (e.g. Rocky Mountain spotted fever [8] , viraemia, fungemia). 
An inflammatory component may be evident. 
 
(v) Intravascular clusters of cancer cells (tumor cell embolism) may occur in 
patients with advanced cancer [9].  
Clinical features of TMAs  
Peripheral blood film features consistent with MAHA include fragmented red 
blood cells (schistocytes), polychromasia and anemia. Quantification of 
fragmentation/schistocytes is not reliably available and remains subjective. 
Laboratory evidence of hemolysis includes elevated lactate dehydrogenase 
(LDH), reticulocytosis, low/absent haptoglobin, and a negative direct 
antiglobulin test. Thrombocytopenia will be evident in the complete blood 
count (CBC) and on the blood film [10].  
 
 Thrombotic thrombocytopenic purpura (TTP) 
Definition of TTP: MAHA with moderate or severe 
thrombocytopenia, with associated organ dysfunction, including 
neurologic, cardiac, gastrointestinal and renal involvement, although 
oliguria or anuric renal failure requiring renal replacement therapy is not 
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typically a feature [10, 11]. TTP is confirmed by a severe deficiency 
(<10%) of ADAMTS13 activity [2, 3] 
TTP is recognized as a multi-organ process with variable clinical features. 
Anemia may not be immediately obvious. Thrombocytopenia is generally 
severe (platelet count <30 x109/L), but higher platelet numbers do not exclude 
the diagnosis.  
Presentation with renal failure requiring renal replacement is not a common 
feature of TTP. However, occasionally patients with multi organ failure may 
develop an acute kidney injury requiring renal support. Congenital TTP (cTTP) 
patients may present with acute renal failure [12].   cTTP cases may 
previously have been misclassified as HUS [13] 
Acute TTP presentations may include bleeding symptoms such as bruising, 
hematuria or thrombotic symptoms associated with neurological or cardiac 
involvement. In practice, TTP is suspected in: 
 Isolated MAHAT  
 New focal neurological symptoms, seizures or myocardial infarction 
(MI), with unexplained MAHAT  
 Prior history of TTP 
  
   
Confirming a diagnosis of TTP:  
Current ADAMTS 13 activity assays provide levels of sensitivity <5% or 1%. 
However, for the diagnosis of TTP, ADAMTS 13 activity levels < 10% are 
diagnostic. This is to include antibody mediated cases and cTTP, including 
late onset cTTP. 
The diagnosis of TTP should be confirmed with ADAMTS 13 activity 
performed on a sample taken prior to initiation of therapy, specifically plasma-
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based.  Samples taken immediately following plasma therapy may give a 
falsely raised ADAMTS 13 activity. The presence of anti-ADAMTS 13 IgG 
antibodies may help confirm TTP in these situations. However, in autoimmune 
TTP, >75% of patients exhibit <10% ADAMTS 13 activity immediately before 
the next therapeutic plasma exchange session for several days after starting 
daily exchange therapy [14].   
Assays at diagnosis should include: ADAMTS 13 activity, functional inhibitor 
based on mixing studies, and/or an anti-ADAMTS 13 IgG. This panel should 
correctly identify TTP patients in the majority of cases.  
Measurement of ADAMTS 13 at regular intervals during treatment and in 
remission (e.g. weekly during treatment, monthly, then 3 monthly during 
follow-up period, extending to 6-12 monthly) may provide data in regard to the 
risk of relapse and persistence of subclinical disease activity [15]. ADAMTS 
13 activity <10% with or without a detectable inhibitor is associated with a 
significant risk of relapse and can guide elective, prophylactic therapy 
preventing further relapse [16-18] in iTTP. 
 Congenital TTP (Upshaw-Schulman syndrome) (cTTP): persistent 
severe deficiency (<10%) of ADAMTS 13 activity, with no evidence of 
anti-ADAMTS 13 autoantibodies, confirmed by molecular analysis of the 
ADAMTS 13 gene confirming a pathogenic homozygous or compound 
heterozygous mutational defect.  
Persistent ADAMTS 13 activity <10% with no detectable anti-ADAMTS 13 IgG 
antibodies (confirmed in the acute phase and in remission after treatment) 
suggests a diagnosis of cTTP, especially in the following circumstances: 
 Neonates presenting with thrombocytopenia, red cell fragmentation on 
blood film, often with hyperbilirubinemia. 
 Children/ adults if there is a familial antecedent of TTP, especially in 
siblings from consanguineous parents. 
 First TTP episode in adulthood, in particular, during pregnancy.  
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The diagnosis of cTTP is confirmed following mutational analysis [19-21].  
Patients can present in the neonatal period, childhood or adulthood, with 
presentations typically associated with a trigger, such as infection, 
vaccination, or dehydration [22]. Pregnancy may precipitate acute 
manifestations in women with cTTP.  Presentation of TTP in pregnancy, often 
associated with fetal loss, particularly in the 2nd trimester, requires exclusion 
of late onset cTTP [23-25].  
The diagnosis is confirmed if pathogenic ADAMTS 13 mutations are identified. 
However, many genetic variants are of unknown significance and require 
expression studies. Infusion of plasma resulting in recovery of ADAMTS 13 
activity and the disappearance of ADAMTS 13 activity with a half life of 2-3 
days, supports the diagnosis of cTTP [26]. 
  Immune mediated TTP (iTTP): 
This defines acquired TTP and can be divided into those cases in which a 
precipitating cause can or cannot be confirmed. All cases require immediate 
therapy (TPE and steroids), but differentiating subgroups can help to tailor 
therapy.  
 Primary iTTP: This describes acquired autoimmune TTP for which 
there is no obvious underlying precipitating cause/disease, ADAMTS 13 
activity <10% with the presence of ADAMTS 13 autoantibodies.  
Primary iTTP accounts for the majority of cases of TTP. The precipitating 
factor or trigger for primary immune TTP has not been identified, although an 
underlying genetic risk in Caucasian patients has reported the presence of 
HLA DQ-7, HLA DRB1*11 & HLA DRB3* [27] 
 Secondary iTTP: This describes acquired autoimmune TTP for 
which a defined underlying disorder or trigger can be identified 
including connective tissue disease (such as systemic lupus 
erythematosis (SLE)), human immunodeficiency virus infection, 
cytomegalovirus (CMV) infection and/or a specific precipitating factor 
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(e.g. pregnancy, drugs). Treatment of the underlying disorder and/or 
removing the underlying precipitant may be required as well as standard 
TTP therapy. The presence of severe deficiency (<10%) of ADAMTS 13 
activity and ADAMTS 13 autoantibodies confirms a diagnosis of TTP. 
Secondary causes include infectious agents such as HIV [28] , drugs, 
such as ticlodipine, quinine, simvastatin [29, 30], trimethoprim [31] , pegylated 
interferon [32], as examples.  The association is typically rare and 
idiosyncratic. Pregnancy or certain autoimmune diseases, such as SLE [33], 
Sjogren’s syndrome [34] and rheumatoid arthritis (RA) maybe associated with 
iTTP. Treatment of the underlying precipitant or stopping implicated drugs in 
conjunction with acute standard therapy (plasma exchange and 
immunosuppression eg steroids) may be necessary. In HIV associated TTP, 
plasma exchange is of value, in conjunction with HAART (highly active 
antiretroviral therapy) [28, 35]. Secondary iTTP constitutes only a small 
proportion of the overall cases of TTP.  
There remain, however, a number of cases that meet the clinical criteria for 
TTP, but with ADAMTS 13 activity levels that are not severely deficient and in 
whom an alternative diagnosis cannot be determined.  In these patients 
treatment with plasma exchange, needs to be individualized and continued 
only if a clear clinical benefit is obvious. Such cases should be discussed with 
expert centres in TTP/HUS. 
 Differential diagnosis of TMA  
There are a number of conditions that have presenting features (both clinical 
and laboratory) similar to TTP. ADAMTS 13 assays are essential in their 
differentiation (Table 1). 
Hemolytic Uremic Syndrome (HUS): HUS is defined by MAHAT and renal 
injury, which is the predominant feature. Thrombocytopenia may not be 
as severe as in TTP, and anemia at presentation can be variable (Figure 
1).  
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Infection Associated HUS (IA- HUS), often referred to as STEC-HUS 
describes an infectious etiology associated typically with E. coli 0157:H7, that 
express Shiga toxin. The TMA presents 5-7 days after the infection with 
hemorrhagic colitis. E coli 0157: H7 is not the only subtype associated with 
infection associated HUS. Indeed other subtypes of E coli [36], Salmonella, 
Shigella, and Campylobacter associated HUS can present similarly. 
Complement Mediated HUS (CM-HUS) usually results from defective 
regulation of the alternative complement pathway [37]. CM-HUS can be 
triggered by infection (and diarrhea may be evident at presentation), 
vaccinations, or pregnancy. Heterozygous mutations may be identified, 
affecting complement regulators including complement factors H (CFH) and I 
(CFI), complement factor H related protein (CFHR1, 3 and 5), CD46 (MCP), 
or gain of function mutations in C3 and complement factor B (CFB). CM-HUS 
associated with anti-complement factor H antibodies (associated with a 
polymorphic deletion of CFHR1) can also occur, particularly in children, and is 
responsive to immunosuppressive therapy [38]. CM-HUS is also described 
associated with defects in other genes, including THBD, which encodes 
thrombomodulin and with bi-allelic mutation of the DGKE gene that encodes 
diacycl glycerol kinase ε, which regulates diacyl glycerol activated Protein 
Kinase C signaling in endothelial cells. While the pathophysiology of DGKE-
associated HUS is not completely understood it is not thought to directly 
involve disruption of complement alternative pathway regulation [39]. 
Mutational analysis may take weeks to be completed and in 40-50% of cases 
no mutations are identified [40].  Therefore, treatment decisions must be 
made on the basis of the clinical presentation and absence of severe 
ADAMTS 13 deficiency. CM-HUS may respond to plasma exchange but 
eculizumab, a humanized monoclonal antibody, which binds to and inhibit C5, 
is more efficacious, except in DGKE-associated disease [41]. In addition, new 
complement inhibitors are being developed.  A C5 polymorphism, described in 
the Japanese population, is associated with a reduced response to 
eculizumab [42].  
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The clinical presentation of CM-HUS can be variable and includes: 
 renal failure, MAHAT;  
 renal failure with MAHA but a normal platelet count;  
 chronic or progressive renal failure, without a history of MAHA;  
 severe hypertension, MAHA or thrombocytopenia, with or without renal 
impairment, often diagnosed by renal biopsy. 
In addition to molecular testing, a response to anti-complement therapy may 
provide confirmation of the diagnosis.  
Rare secondary causes have been identified causing HUS [43](Table 1).  
. 
 
Definition of hematological response to treatment 
Clinical Response: Sustained normalization of platelet counts above the 
lower limit of the established reference range (eg >150x109/L) and LDH 
(<1.5 upper limit of normal (ULN)) after cessation of plasma exchange. 
Clinical Remission:  Clinical response after cessation of plasma 
exchange and maintained for greater than 30 days. 
Clinical response and clinical remission would be associated with stabilization 
of parameters if end organ damage is severe or improvement in function with 
normalization of laboratory parameters.  
Exacerbation: reduction in platelet count to below the lower limit of the 
established reference range (eg<150 x 109/L), increased LDH, and the 
need to restart plasma exchange within 30 days of the last  plasma 
exchange after a clinical response to plasma exchange. 
Relapse: Fall in platelet count to below the lower limit of the established 
reference range (eg <150 x 10^9/L), +/- clinical symptoms >30 days after 
stopping plasma exchange for an acute TTP episode, requiring re-
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initiation of therapy. This is usually associated with a new increase in 
LDH. 
In patients achieving a normal platelet count, a >10% reduction within 24 
hours may represent impending exacerbation (during a period of daily plasma 
exchange therapy or within 30 days of stopping plasma exchange) or relapse 
and requires close monitoring.  Exacerbation or relapse may not demonstrate 
the full spectrum of  clinical features seen in the initial acute TTP presentation. 
ADAMTS 13 activity will be  <10% at exacerbation/relapse, either as a 
persisting deficiency or a de novo deficiency after transient normalisation.  
Refractory TTP:  Persistent thrombocytopenia, lack of sustained platelet 
count increment or platelet counts <50 x109/L and persistently raised 
LDH (>1.5 X ULN) despite 5  plasma exchange [44] and steroid 
treatment.  This would be defined as SEVERE if the platelet count 
remained < 30 x 109/L. 
Normalization of a platelet count is typically above the lower limit of the 
established reference range (eg >150x109/L), however, country/regional 
variability relating to the ‘normal range’ should be noted. LDH may not be in 
the normal laboratory range with clinical response or remission, but 
decreasing levels with increasing platelet counts is in keeping with clinical 
response. 
The definition of refractory TTP can be challenging. Cases with an initial 
response, but then a reduced platelet count that is difficult to increase, may be 
considered refractory and this may occur after 5  plasma exchange 
procedures. However, the clinical condition is likely to be more stable at this 
point. 
Intensive plasma exchange refers to increased volumes per plasma exchange 
eg a single volume to 1.5 plasma volume or increased frequency of plasma 
exchange eg twice daily. Protocols will be institution specific. 
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During an acute presentation, the definition of refractory disease may require 
an escalation in therapy. The median time to achieve a clinical response, with 
daily plasma exchange, is approximately 10-15 days [45].  Patients admitted 
to an ICU setting with neurological and /or cardiac features may require longer 
plasma exchange therapy [46].  Patients failing to achieve remission or whose 
platelet count and LDH initially improve but worsen despite on-going 
treatment would also be considered to have refractory disease.   
Relapsing TTP: 
There are a number of identified risk factors that may be associated with 
or precipitate a relapse of iTTP,  
 ADAMTS 13 deficiency (particularly <10% activity) 
 Persistent severe ADAMTS 13 deficiency in remission 
 Persistent anti-ADAMTS 13 antibodies in remission 
or congenital  disease 
 Pregnancy  
 Infection/live vaccinations  
 Drugs including drugs of abuse eg. cocaine, alcohol  
 
In iTTP, a severely reduced ADAMTS 13 activity persisting during remission is 
associated with relapse, particularly when associated with inhibitory 
autoantibodies [47]. Therapy should be considered to clear antibodies and 
normalize ADAMTS 13 activity, in patients felt to be at high risk for relapse 
[16, 18]. Pregnancy [48] , infections and live vaccinations in particular may 
precipitate an acute episode of cTTP. Often, an initial acute TTP episode, 
even though occurring only in adulthood, is followed by recurrent episodes 
[49]. 
 Factors relating to severity/prognosis of TTP 
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 Presence of Anti-ADAMTS 13 IgG antibody associated with severe 
ADAMTS 13 deficiency 
 Raised troponin at presentation 
 Presence of neurological features 
 Older age 
 Low ADAMTS 13 antigen at presentation 
There are few predictors of disease severity, but necessity of intubation and 
ventilation, older age, neurological features [50]and cardiac symptoms and/or 
raised troponin,[51] with high inhibitor levels/IgG autoantibodies to ADAMTS 
13 are key predictors.  Ethnicity and ADAMTS 13 activity <10% are 
associated with exacerbation and relapse respectively. Non Caucasians have 
increased exacerbation and relapse, but reduced mortality.  Inhibitor or anti-
ADAMTS 13 IgG levels predicting the severity of disease have not been 
defined [52], but levels (anti-ADAMTS 13 IgG >50% or > 2 BU/ml) are 
associated with a poorer outcome [51]. Low ADAMTS 13 antigen level at 
presentation may be associated with worse clinical outcome in iTTP [53]. 
Routine laboratory parameters such as platelet count, LDH, and hemoglobin 
are not predictive of severity, although failure to improve with therapy and 
hence refractory disease is associated with a worse outcome.  
ADAMTS 13 assays: 
ADAMTS 13 activity: determines the amount of functional ADAMTS 13 via 
direct or indirect measurement of VWF cleavage. Current methods include 
FRETS-VWF73, chromogenic VWF-73 [54], chromogenic VWF-73 [55], 
FRETS-rVWF71 [56] FRET-VWF86 and SELDI-TOF mass spectrometry [57]. 
A standard curve using pooled normal plasma (PNP) for each assay plus 
control samples (e.g. plasma of a cTTP patient for an   low range sample; the 
WHO 1st International Standard ADAMTS 13 [58]), which have undergone in-
house calibration.  
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ADAMTS 13 antigen: determines the amount of ADAMTS 13 protein in 
plasma. Low levels appear to be associated with poor prognosis [53]. 
Anti-ADAMTS 13 antibodies: usually IgG but IgM and IgA may be also 
relevant. Anti-ADAMTS 13 antibodies are measured by ELISA, Western blot 
or immunoprecipitation. ADAMTS 13 antibodies by ELISA may be seen in 
5%-10% of healthy individuals however, this may be manufacturer/assay 
dependent [59]. ELISA or Western blotting using recombinant ADAMTS 13 to 
detect anti-ADAMTS 13 in patient’s plasma can assess the presence of anti-
ADAMTS 13 antibodies. In-house or commercially available assays should 
have appropriate validation and controls to include low, medium and high 
antibody titres.  
 
ADAMTS 13 inhibitor assays: identifies and quantitates anti-ADAMTS 13 
antibodies that functionally inhibit ADAMTS 13 in vitro. Functional ADAMTS 
13 inhibitors are assessed in classical Bethesda-like mixing studies. Samples 
are heat-inactivated for 30 minutes at 56°C to abolish endogenous ADAMTS 
13, before mixing, at various dilutions,  with PNP.  After incubation at 37°C for 
2 hours, residual ADAMTS 13 activity is measured and the residual activity 
transformed in Bethesda units,(1BU/ml of inhibitor inhibits 50% of normal 
plasma ADAMTS 13).  For routine purposes it is usually sufficient to titrate up 
to 2 Bethesda units/ml.   
 
Factors affecting ADAMTS 13 levels 
Severe hemolysis with marked hyperbilirubinemia [60]or severe lipemia may 
give falsely low ADAMTS 13 activity results, particularly when using 
fluorogenic detection e.g. FRETS [54]; Free hemoglobin in plasma from 
intravascular hemolysis can also inhibit ADAMTS 13 activity [61]. 
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There is good concordance between assays in the range of severe deficiency 
of ADAMTS 13 (defined as either <5% or <10%).  However assay conditions 
can affect results. There are numerous variables in quantification of ADAMTS 
13 activity levels among different platforms or when performed in different 
laboratories. Further studies involving large series of plasma samples are 
needed to evaluate the newly developed commercial kits. 
Pre-analytic aspects: specimen type and acceptability criteria  
 ADAMTS 13 activity can be assessed in citrated plasma, serum or lithium-
heparin plasma. While extensive comparisons between these are missing, 
small series demonstrate equality [62].  EDTA plasma is not suitable for 
ADAMTS 13 activity testing, as it is an irreversible inhibitor of ADAMTS 13 
activity.  
Evaluation of assays 
- Detection (sensitivity) limit of the method:  
. For ADAMTS 13 activity measurement (defined as the lowest  activity 
that is distinguishable from buffer or heat inactivated plasma 
respectively): this should be < 5%, but preferably < 1%.  
. For the detection of inhibitors:  difficult to standardize, but a negative 
control and at least 2 positive antibody controls, which have demonstrated 
reproducibility with the technique, should be considered. The detection limit is 
approximately 0.4-0.6 BU/ml. 
- Precision of the method: intra-assay reproducibility (within series), inter-
assay reproducibility (between run in one given laboratory and also inter-
laboratory precision): should have CVs of  <10%. 
In conclusion, we have developed definitions for TTP and associated TMAs 
that we hope will promote uniformity in publications, associated studies and 
clinical trials. The field is ever expanding and the group will be required to 
undertake a review again in future years.  
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Disease Summary of Disease Comment 
TTP Acute haematological 
emergency, requiring 
prompt diagnosis and 
treatment. More likely to 
have 
neurological/cardiac 
features-but a multi 
system disorder. 
ADAMTS 13 measured 
for definitive diagnosis. 
Plasma exchange is the 
mainstay of treatment, 
typically additional  
immunomodulating 
therapy required in iTTP. 
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HUS 
 
 
A. IA-HUS 
 
 
 
The TMA presents 5-7 
days after the infection 
with haemorrhagic 
colitis. 
 
 
 
 
Confirmation of infection 
is serological and/PCR. 
B  CM-HUS CM-HUS can be 
triggered by infection 
(and diarrhoea maybe 
present at presentation), 
vaccinations, or 
pregnancy. . 
 
Diagnosis may be 
confirmed by 
complement mutations 
eg CFH, CFI, MCP, 
CFB, C3 or anti CFH 
antibodies. Homozygous 
or compound 
heterozygous 
diacylglycerol kinase 
(DGKE) mutations  
typically do not respond 
to current complement 
inhibitors [39]  Treatment 
decisions must be made 
on the basis of the 
clinical presentation and 
absence of severe 
ADAMTS13 deficiency. 
A response to anti-
complement therapy 
may provide 
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confirmation of the 
diagnosis. 
C. Streptococcus  
pneumoniae 
This is seen almost 
exclusively in young 
children. Typically 
present with pneumonia. 
Incidence reduced since 
polyvalent vaccine (in 
some countries). Have a 
DAT positive haemolytic 
anaemia 
Thomsen-Friedenreich 
cryptoantigen, present 
on red cells, platelet, 
glomeruli and 
hepatocytes are 
exposed by 
neuramindase, produced 
by all subtypes of 
Streptococcus 
pneumoniae. The TF 
antigen interacts with 
IgM antibodies, resulting 
in agglutination. 
Treatment is supportive, 
but still washed blood 
products may be 
requested [63] 
 33 
 
D. Cobalamin C 
deficiency 
A rare cause of HUS that 
is caused by recessive 
mutations of the 
methylmalonic aciduria 
(cobalamin deficiency) 
cblC type, with 
homocystinuria 
(MMACHC) gene. 
Presentation is typically 
within the first year of life 
[64]. 
 
 
Connective tissue 
disease 
MAHAT may be a 
primary feature. Further 
systemic 
features/laboratory 
testing confirm the 
diagnosis 
Autoimmune screen, 
tissue biopsy eg SLE, 
scleroderma, 
antiphospholipid 
syndrome, vasculitis (eg 
ANCA) 
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Transplantation, either 
solid organ or bone 
marrow/ hematopoietic 
stem cell (HSC): 
May present with 
MAHAT with or without 
renal involvement. It is 
typically associated with 
immunosuppressive 
therapy, such as 
Tacrolimus, Ciclosporin 
A, underlying 
opportunistic infections 
(eg CMV, Adenovirus, 
Aspergillus) or graft-
versus-host disease [65],  
 HSC transplant 
associated TMAs do not 
have severe ADAMTS13 
deficiency (ie <10%). 
Complement alternative 
pathway dysregulation 
may be involved in the 
pathogenesis of HSCT-
TMA . In patients 
developing  TMA post 
renal transplantation, 
consideration should be 
given to possible CM-
HUS, which may have 
been  the cause of the 
initial renal failure and 
the failed  transplanted 
kidney [66] 
 
Disseminated 
intravascular 
Coagulation (DIC) 
DIC is associated with 
abnormalities in routine 
coagulation and CBC 
screens [67]. 
 DIC is typically due to an 
underlying precipitant 
such as sepsis, 
malignancy, 
haematological 
disorders, obstetric 
complications or trauma. 
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Pregnancy associated 
TMAS 
Preeclampsia and 
HELLP occur in the 
second half of 
pregnancy or early post 
partum.  
 Complement activation 
in HELLP or 
preeclampsia may 
trigger the development 
of TMA. Complement 
abnormalities have been 
identified in some cases 
of HELLP/PE [68],  
A. HELLP syndrome There are no specific 
diagnostic clinical or 
laboratory factors. 
ADAMTS13 activity is 
typically normal. HELLP 
can be divided into type 
1, 2 and 3 based on the 
platelet count (<50 
x109/L, 50-100 x109/L, 
100-150 x109/L) [69].  
 
May be associated with 
complications such as 
DIC, and placental 
abruption. 
  
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B. Pre-eclampsia Defined as de novo 
hypertension (>140/90 
mm Hg) and proteinuria 
(>0.3 g per 24 hours) 
after 20 weeks of 
gestation . 
Control of BP. Delivery 
will improve the 
situation. 
Drugs Ticlodipine [70] may be 
associated with 
autoantibodies to 
ADAMTS 13, case 
reports with  quinine 
[71], simvastatin, 
trimethoprim or 
interferon. Clopidogrel is 
not associated with TTP. 
TMA may occur with 
gemcitabine, bleomycin, 
and mitomycin. VEGF 
inhibitors were 
associated with features 
of TMA reminiscent of 
HUS [72]. 
Stopping the offending 
drug maybe associated 
with improvement.  
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Table 1: Summary of characteristics associated with conditions 
presenting with microangiopathic haemolytic anaemia and 
thrombocytopenia (MAHAT) 
IR-HUS: Infection related haemolytic uraemic syndrome; PEX: plasma 
exchange, BP: blood pressure, HELLP: haemolysis, elevated liver enzymes & 
low platelets, DIC: disseminated intravascular coagulation,  TMA: thrombotic 
microangiopathy, CM-HUS: . Complement mediated-HUS 
Pancreatitis Caused by alcohol 
excess, bile duct 
obstruction or possibly 
an autoimmune 
precipitant [73].  
ADAMTS13 levels may 
not be severely reduced 
[74]. Identifying  the 
underlying condition 
reduces the risk of 
further relapses.  
 
Malignancy In patients with MAHAT 
for whom a severe 
deficiency of ADAMTS13 
activity is not confirmed, 
tumour markers and 
radiological 
investigations should be 
considered [75].  
 
ADAMTS13 activity is 
normal or mildly 
decreased. 
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MAHAT: 
MAHA  and 
thrombocytopenia  
TTP: Multiorgan disease, 
clinical features variable. 
Confirmed by ADAMTS 13 
activity <10% 
Haemolytic Uraemic 
Syndrome: usually 
affects the kidney 
Other conditions 
associated with  
TMA presenting 
with MAHAT  
IA-HUS: Identification of  
infectious cause or its 
toxin using stool culture, 
serology and/ or PCR 
 Complement Mediated HUS. 
Complement mutational analysis 
and anti CFH antibodies should be 
undertaken, but a negative result 
does not exclude disease. 
Diagnosis is by exclusion of all 
other precipitating causes and 
ADAMTS 13 activity > 10% (and 
no evidence of  ADAMTS 13 
autoantibodies. 
Figure 1: Differential diagnosis of  thrombotic Microangiopathies presenting 
with MAHAT 
 
Key: MAHA: microangiopathic haemolytic anaemia; MAHAT: MAHA and 
thrombocytopenia TTP: thrombotic thrombocytopenic purpura; IA-HUS: Infection 
associated HUS, PCR: polymerase chain reaction 
